---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-226837"
form_type: "8-K"
ticker: "CPRX"
cik: "0001369568"
company_name: "CATALYST PHARMACEUTICALS, INC."
filed_at: "2025-10-01T23:59:59+00:00"
generated_at: "2026-05-17T05:03:32.356016+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Catalyst Pharma announces $200M share repurchase program through Dec 2026

## Summary
- Board authorized up to $200M share repurchase from Oct 1, 2025 to Dec 31, 2026.
- Company had >$650M cash & equivalents and no funded debt as of June 30, 2025.
- Repurchases may be via open market or privately negotiated; timing depends on stock price and conditions.
- Program may be suspended or terminated anytime; no obligation to buy any specific amount.
- Company plans to use existing cash on hand to fund the repurchase program.

## SEC filing metadata
- accession: 0001193125-25-226837
- form_type: 8-K
- ticker: CPRX
- cik: 0001369568
- company_name: CATALYST PHARMACEUTICALS, INC.
- filed_at: 2025-10-01T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1369568/000119312525226837/0001193125-25-226837-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1369568/000119312525226837/d118298d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-226837
- JSON: https://secwatch.observer/filing/0001193125-25-226837.json
- Plain text: https://secwatch.observer/filing/0001193125-25-226837.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.